Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience

dc.authorid0000-0003-3868-3268
dc.authorid0000-0003-1956-2348
dc.contributor.authorAtas, Halil
dc.contributor.authorSahin, Ahmet Anil
dc.contributor.authorAtas, Dilek Barutcu
dc.contributor.authorSunbul, Murat
dc.contributor.authorKepez, Alper
dc.contributor.authorAğırbaşlı, Mehmet
dc.date.accessioned2025-05-10T19:41:31Z
dc.date.issued2018
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractTime in therapeutic range (TTR) of international normalized ratio is crucial for the safety and efficacy of anticoagulation with warfarin and it is influenced by many factors. There are limited data about the quality of warfarin therapy and its effects on clinical outcomes in Turkey. The aim of this study is to demonstrate the quality of anticoagulant therapy with warfarin and evaluate the parameters that affect the quality of warfarin therapy. A total of 170 patients with atrial fibrillation (AF; mean age: 62.2 +/- 13.3; 69.2% female) treated with warfarin were included in this study. The mean follow-up period was 20 +/- 8.4 months. The mean TTR levels of all patients were found to be 54.2% +/- 21.4%. The TTR levels were similar in patients with valvular AF (VAF) and nonvalvular AF (NVAF). Logistic regression analysis revealed that elderly, heart failure (HF), and renal dysfunction were independent predictors of lower TTR. There were no significant differences between the VAF and NVAF subgroups regarding the incidence of mortality, stroke, and myocardial infarction. Cox regression analysis revealed that HF, coronary artery disease, and renal dysfunction were independent predictors of clinical outcomes in addition to lower TTR. Our results provide data regarding the quality of anticoagulation with warfarin from a single tertiary center in Istanbul, Turkey. The questions remain in seeking quality improvement in anticoagulation.
dc.identifier.doi10.1177/1076029617695484
dc.identifier.endpage541
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue3
dc.identifier.pmid28301912
dc.identifier.scopus2-s2.0-85041923642
dc.identifier.scopusqualityQ2
dc.identifier.startpage536
dc.identifier.urihttps://doi.org/10.1177/1076029617695484
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10357
dc.identifier.volume24
dc.identifier.wosWOS:000429775000022
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectwarfarin
dc.subjecttime in therapeutic range
dc.subjectheart failure
dc.titlePotential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10357.pdf
Boyut:
194.62 KB
Biçim:
Adobe Portable Document Format